EYPT
EYPT clinical trials: EyePoint, Inc.
Every trial on ClinicalTrials.gov where EyePoint, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 20
- Trials linked
- 19
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
EYPT on the catalyst calendar · EYPT registry changes
- Primary completion Sep 9, 2026ActualPhase 3NCT06683742A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at...EyePoint Pharmaceuticals, Inc. · Wet Age Related Macular DegenerationActive, not recruitingEYPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 13, 2026ActualPhase 3NCT06668064A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at...EyePoint Pharmaceuticals, Inc. · Wet Age Related Macular DegenerationActive, not recruitingEYPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2027Sponsor estimatePhase 3NCT07449936COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEEyePoint Pharmaceuticals, Inc. · Diabetic Macular EdemaActive, not recruitingEYPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2027Sponsor estimatePhase 3NCT07449923CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEEyePoint Pharmaceuticals, Inc. · Diabetic Macular EdemaActive, not recruitingEYPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 22, 2025ActualPhase 4NCT05191706Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood CataractEyePoint Pharmaceuticals, Inc. · CataractTerminatedEYPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 29, 2023ActualPhase 2NCT05381948Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)EyePoint Pharmaceuticals, Inc. · Wet Age-related Macular DegenerationCompletedEYPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 12, 2024ActualPhase 2NCT05383209Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)EyePoint Pharmaceuticals, Inc. · Nonproliferative Diabetic RetinopathyCompletedEYPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2023Sponsor estimatePhase 3NCT05550350A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract SurgeryEyePoint Pharmaceuticals, Inc. · CataractWithdrawnEYPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 24, 2024ActualPhase 2NCT06099184Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)EyePoint Pharmaceuticals, Inc. · Diabetic Macular EdemaCompletedEYPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 12, 2023ActualPhase 3NCT05070728Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) InsertEyePoint Pharmaceuticals, Inc. · UveitisTerminatedEYPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2023Sponsor estimatePhase 3NCT05550363A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2)EyePoint Pharmaceuticals, Inc. · CataractWithdrawnEYPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 11, 2022ActualPhase 1NCT04747197First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)EyePoint Pharmaceuticals, Inc. · Wet Age-related Macular DegenerationCompletedEYPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 26, 2021ActualPhase 2NCT04511650Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019EyePoint Pharmaceuticals, Inc. · COVID-19TerminatedEYPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 9, 2019ActualPhase 2NCT03197870The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy...EyePoint Pharmaceuticals, Inc. · Nonproliferative Diabetic RetinopathyCompletedEYPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 5, 2020ActualPhase 2NCT04405245Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With...EyePoint Pharmaceuticals, Inc. · Ocular HypertensionCompletedEYPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 1, 2020ActualNo phase registeredNCT04290676DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001EyePoint Pharmaceuticals, Inc. · CataractCompletedEYPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 26, 2018ActualPhase 3NCT01694186Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal InsertEyePoint Pharmaceuticals, Inc. · Non-Infectious UveitisCompletedEYPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 4, 2019ActualPhase 3NCT02746991Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior UveitisEyePoint Pharmaceuticals, Inc. · Posterior UveitisCompletedEYPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 17, 2017ActualPhase 3NCT02748512Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious UveitisEyePoint Pharmaceuticals, Inc. · Non-Infectious UveitisCompletedEYPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 22, 2022ActualPhase 4NCT04781335"A Prospective Study of the Efficacy of Intracameral Dexamethasone (Dexycu™) Compared to Standard of Care Treatment for Post-Cataract...The Eye Institute of West Florida · CataractCompletedEYPTCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 20 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner